PharmaFocus Today – media

Vitamin D supplementation linked to improved cardiometabolic health

A latest systematic review and meta-analysis conducted by scientists from institutions across China and the United States has uncovered promising insights into how vitamin D supplementation can significantly impact cardiometabolic health. The study, which was published in Engineering, has implications for tailored therapeutic strategies targeting cardiovascular diseases and related risks. The comprehensive review analyzed 99 randomized controlled trials (RCTs) involving a total of 17 656 participants. The analysis revealed that vitamin D supplementation, with a median dose of 3320 International Units (IU) per day, was associated with favorable effects on various cardiometabolic risk factors, including reductions in systolic and diastolic blood pressure, total cholesterol, fasting blood glucose, hemoglobin A1C, and fasting blood insulin. Significantly, the researchers discovered that the benefits of vitamin D supplementation were most pronounced in specific groups: non-Western populations, individuals with baseline 25-hydroxyvitamin D levels below 15.0 ng·mL−1, those with a body mass index (BMI) below 30 ...
- Source: drugdu
- 32
- August 7, 2025
Dizzy, Heart Racing After You Stand? New Treatment Proposed

By Dennis Thompson HealthDay ReporterWEDNESDAY, Aug. 6, 2025 (HealthDay News) — Some people find that when they stand, their hearts tend to race and they get dizzy and lightheaded. This is due to a rare condition called postural orthostatic tachycardia syndrome, or POTS – and doctors think they’ve found a potential treatment. An established heart failure drug called ivabradine appears to provide lasting relief for people suffering from POTS, according to results from a pilot study. The drug kept POTS patients’ hearts from racing and significantly improved other symptoms while not affecting their overall blood pressure, researchers recently reported in the Journal of Cardiovascular Pharmacology. “These data suggest that the inappropriate increase in heart rate is exactly why patients feel sick, and that reducing the heart rate with a medication that does not affect blood pressure can make a difference in the quality of life,” senior researcher Dr. Antonio ...
- Source: drugdu
- 32
- August 7, 2025
Announcement on Obtaining Orphan Drug Designation from the U.S. FDA

On the evening of August 6, Hengrui MedicineThe company recently received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its Ruikang trastuzumab injection, combined with adebelimumab injection and chemotherapy, for the treatment of gastric cancer or gastroesophageal junction adenocarcinoma. Orphan drugs, also known as rare disease drugs, are used to prevent, treat, or diagnose rare diseases. This FDA orphan drug designation provides the company with opportunities to benefit from U.S. policy support in product development, registration, and commercialization. https://finance.eastmoney.com/a/202508063477857963.html
- Source: drugdu
- 28
- August 7, 2025
HEC Pharmaceuticals is listed on the Hong Kong Stock Exchange today

On August 7, Guangdong HEC Pharmaceutical Co., Ltd. (hereinafter referred to as ” HEC Pharma “) was listed on the Main Board of the Hong Kong Stock Exchange Limited (hereinafter referred to as “HKEX”). As the first H-share merger and privatization plus introduction case, HEC Pharma merged its Hong Kong-listed subsidiary Yichang HEC Pharmaceutical with the acquisition ofChangjiang Pharmaceutical Co., Ltd. has been fully listed. This is not only a milestone in the development history of this company that has been deeply engaged in innovation for 20 years, but also marks the beginning of the development of China’s innovative drugs.Asset SecuritiesThis is a breakthrough in the exploration of localization and internationalization. Industry insiders pointed out that this move not only breaks the time barrier of traditional capital operation methods, reduces the financial friction costs generated by corporate acquisitions, and realizes the connection between resource integration and capital upgrading, but also ...
- Source: drugdu
- 27
- August 7, 2025
Kelun Botai’s market value exceeds 100 billion

Today (August 5), Kelun Biotech’s market capitalization exceeded HK$100 billion for the first time, becoming a highly anticipated company in the innovative pharmaceutical sector. This is not only a milestone for the company itself, but also a significant milestone in the development of innovative pharmaceutical companies in China. The rise in Kelun Botai’s stock price can be described as an inspirational story of ups and downs. Since its listing on the Hong Kong Stock Exchange in July 2023, its share price and market capitalization have experienced a turbulent journey. Initially, despite the promise of a robust pipeline of innovative drugs, the company suffered a significant blow when two early-stage ADC programs in collaboration with Merck were terminated from clinical development, sending its share price into a brief downturn. However, the uncertainties surrounding innovative drug development haven’t hindered Kelun Biotech’s progress. In June 2024, the company, like a rising star, announced ...
- Source: drugdu
- 28
- August 7, 2025
Australian study finds lasting relief for back pain through cognitive functional therapy

Australian research has shown that a personalized program that helps people with chronic, disabling low back pain better understand their condition and take charge of its management produces large benefits that are sustained over three years. In the RESTORE trial, conducted at centres in Sydney and Perth, a seven-session program of cognitive functional therapy (CFT) delivered by specially trained physiotherapists significantly reduced people’s back pain and improved their function, compared with usual care. Data just published in medical journal The Lancet Rheumatology show these improvements were largely maintained over three years of follow-up. The persistent effect of CFT over time is a new and very important finding, says lead author Professor Mark Hancock, Professor of Physiotherapy at Macquarie University. “This the first large, high-quality study investigating the long-term impact of CFT, and shows that it’s effective and remains effective. In fact, our previous systematic review shows there are relatively few ...
- Source: drugdu
- 38
- August 6, 2025
New Drug May Fight a Deadly Bone Marrow Disorder

By Dennis Thompson HealthDay ReporterTUESDAY, Aug. 5, 2025 (HealthDay News) — A recently approved leukemia pill also might help some patients diagnosed with a deadly bone marrow disorder, a new pilot study says. About 3 in 5 patients with myelodysplastic syndrome (MDS) responded to treatment with olutasidenib (Rezlidhia), which the U.S. Food and Drug Administration (FDA) approved in 2022 for patients with acute myeloid leukemia, researchers reported recently in the journal Blood Advances. What’s more, about two-thirds of patients who previously required regular blood transfusions for the condition no longer needed them, results show. “We saw really quite remarkable outcomes in a very high-risk MDS population, not only in response rates, but also in blood count improvement, long duration of response and improved overall survival,” lead researcher Dr. Justin Watts, chief of the leukemia section at the University of Miami Sylvester Comprehensive Cancer Center, said in a news release. The ...
- Source: drugdu
- 39
- August 6, 2025
Sanofi withdraws lipid-lowering drug Praluent from Chinese market

On August 4, a reporter from the International Financial News learned from SanofiChina has learned that the company has stopped supplying its new lipid-lowering drug, Praluent (alirocumab injection), to the Chinese market. The main reasons for the suspension are global supply issues and the company’s cardiovascular market strategy and pipeline optimization. According to industry media reports, many hospitals have recently received official notifications from Sanofi . Praluent confirms his withdrawal According to the data, Praluent is a new lipid-lowering drug of the PCSK9 inhibitor class, which is mainly used for the prevention of cardiovascular events, primary hypercholesterolemia (including heterozygous familial and non-familial hypercholesterolemia) and mixed dyslipidemia. The drug is one of the first PCSK9 monoclonal antibodies to be marketed in the world. It was approved in the United States in 2015 and was included in the China Innovative Drug List in 2019.It will be included in the priority review catalog, ...
- Source: drugdu
- 41
- August 5, 2025
Menopa’s subsidiary, Lurasidone Hydrochloride API, received approval

On August 4, Mino Pharma(603538) announced that its subsidiary Anhui Minova Pharmaceutical Chemical Co., Ltd.’s lurasidone hydrochloride API has passed the CDE technical review of the National Medical Products Administration and obtained the ” Chemical Raw Materials”The drug’s registration number is Y20230000666, and its indication is the treatment of schizophrenia. The R&D investment totaled 1.35 million yuan (unaudited). The approval of the lurasidone hydrochloride API confirms that the product meets the relevant national drug registration requirements and is eligible for sale in the domestic market. This will further enrich the company’s product line, expand its business scope, and enhance its advantages in the integrated production of APIs and preparations. According to the IMS database, global sales of preparations for this product are expected to reach approximately US$309 million in 2024, with API sales reaching 13,457.74 kilograms. In the first quarter of 2025, Minopharm achieved revenue of 276 million yuan and ...
- Source: drugdu
- 39
- August 5, 2025
These 4 new drugs have no American subjects, but are listed in the United States

As global drug research and development enters a period of clinical globalization and diversified approval pathways, how drug regulatory agencies evaluate and accept data from different sources is no longer just a matter of technical judgment, but also involves institutional mutual trust, geopolitics, and even the reshaping of the industrial landscape. According to the FDA’s “Drug Trials Snapshots 2024” report, the FDA approved four drugs in 2024 without any U.S. subjects involved. This rare move was widely interpreted as the FDA’s loosening of its stance on global data sources under certain conditions. Zero American Subjects: Analyzing Trend Changes from Individual Cases In 2024, the FDA approved 50 new drugs, four of which did not include any U.S. subjects at all. The four drugs are: EXBLIFEP (drug for complicated urinary tract infections), PIASKY (a rare disease treatment for paroxysmal nocturnal hemoglobinuria), TEVIMBRA (a PD-1 drug for esophageal cancer), and UNLOXCYT (for ...
- Source: drugdu
- 33
- August 5, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.